1-4 of 4
Keywords: DLQI
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Suffering and Quality of Life Impairment in Patients with Eczematous Diseases: Results from an Observational Study Assessing the Relevance of the Involvement of Two Sensitive Body Sites, Namely, the Face and Hands

Subject Area:
Topic Article Package: ADC (Antibody-Drug Conjugates) , Karger e-Journal Backfile Collection 2023 , Dermatology , Immunology and Allergy
Monica Corazza, Maria Elena Flacco, Natale Schettini, Alessandro Borghi
Journal: Dermatology
Dermatology (2023) 239 (3): 368–378.
https://doi.org/10.1159/000528822
Published Online: 13 June 2023
... diseases affecting the face or hands; (2) any differences in QoL impairment in the case of face versus hand involvement; (3) sensitivity of Pictorial Representation of Illness and Self Measure (PRISM) and Dermatology Life Quality Index (DLQI) in measuring disease-related burden. Methods: Adults...
View article titled, Suffering and Quality of Life Impairment in Patients with Eczematous Diseases: Results from an Observational Study Assessing the Relevance of the Involvement of Two Sensitive Body Sites, Namely, the Face and Hands
Open the PDF for Suffering and Quality of Life Impairment in Patients with Eczematous Diseases: Results from an Observational Study Assessing the Relevance of the Involvement of Two Sensitive Body Sites, Namely, the Face and Hands in another window
Journal Articles

The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis

Subject Area:
Karger e-Journal Backfile Collection 2023 , Dermatology , Immunology and Allergy
Jenny M Norlin, Sofia Löfvendahl, Marcus Schmitt-Egenolf
Journal: Dermatology
Dermatology (2023) 239 (2): 262–266.
https://doi.org/10.1159/000528007
Published Online: 10 March 2023
... (DLQI) ≤5. Methods: A longitudinal, observational study based on the Swedish National Registry for Systemic Treatment of Psoriasis, PsoReg. Patients using IL-17/IL-23 inhibitors with assessments of PASI, DLQI, and EQ-5D before (maximum 6 months) and after (3–12 months) initiation of IL-17/IL-23 were...
View article titled, The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis
Open the PDF for The Use of IL-17 and IL-23 Inhibitors in Swedish Clinical Practice: A Register-Based Analysis in another window
Journal Articles

Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (DLQI): Further Data

Subject Area:
Dermatology , Immunology and Allergy
M.K.A. Basra, M.S. Salek, L. Camilleri, R. Sturkey, A.Y. Finlay
Journal: Dermatology
Dermatology (2015) 230 (1): 27–33.
https://doi.org/10.1159/000365390
Published Online: 20 January 2015
...M.K.A. Basra; M.S. Salek; L. Camilleri; R. Sturkey; A.Y. Finlay Aims: To determine the minimal clinically important difference (MCID) of the Dermatology Life Quality Index (DLQI) and its responsiveness to change in inflammatory skin diseases. Methods: A longitudinal study: at stage 1, patients...
View article titled, Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (<span class="search-highlight">DLQI</span>): Further Data
Open the PDF for Determining the Minimal Clinically Important Difference and Responsiveness of the Dermatology Life Quality Index (<span class="search-highlight">DLQI</span>): Further Data in another window
Journal Articles

Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice

Subject Area:
Dermatology , Immunology and Allergy
Jenny M. Norlin, Katarina Steen Carlsson, Ulf Persson, Marcus Schmitt-Egenolf
Journal: Dermatology
Dermatology (2013) 225 (4): 326–332.
https://doi.org/10.1159/000345715
Published Online: 16 January 2013
... and severity index (PASI) and quality of life by the EQ-5D questionnaire and dermatology quality of life index (DLQI) in psoriasis patients who switched from conventional systemic treatment to biological agents in clinical practice. Furthermore, to analyse patient groups with the highest benefit of biological...
View article titled, Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice
Open the PDF for Switch to Biological Agent in Psoriasis Significantly Improved Clinical and Patient-Reported Outcomes in Real-World Practice in another window